Global Adult Vaccines Market to Reach USD 37.18 Billion by 2033 Amid Rising Immunization Awareness and Ageing Population

The global adult vaccines market is witnessing significant momentum as governments, healthcare organizations, and pharmaceutical companies intensify efforts to improve adult immunization rates worldwide. According to Renub Research, the Global Adult Vaccines Market was valued at USD 21.77 billion in 2024 and is projected to reach USD 37.18 billion by 2033, growing at a CAGR of 6.13% during the forecast period 2025 to 2033.

The market is rapidly evolving as adult immunization becomes a central pillar of preventive healthcare strategies globally. Increased prevalence of infectious diseases, rising awareness about vaccine-preventable illnesses, and ageing populations are creating sustained demand for adult vaccines across developed and emerging economies.

Adult vaccines are specifically formulated for individuals aged 18 years and older to prevent serious infectious diseases such as influenza, hepatitis, pneumococcal infections, shingles, HPV, meningococcal disease, and tetanus. While childhood vaccination programs have traditionally dominated immunization policies, healthcare authorities are now placing greater emphasis on adult vaccination to reduce hospitalization rates, healthcare costs, and disease burden among ageing populations.

Download Free Sample Report:

Ageing Population Emerging as a Major Market Driver

One of the strongest growth catalysts for the global adult vaccines market is the rapidly growing elderly population worldwide. Older adults are more vulnerable to infectious diseases due to weakened immune systems, a condition commonly known as immunosenescence.

Healthcare experts increasingly recommend vaccines such as influenza, shingles, pneumococcal, and hepatitis vaccines for elderly individuals to prevent severe complications. According to global demographic projections, one in six people worldwide will be aged 60 years or older by 2030, while the number of people aged 80 and above is expected to triple by 2050.

This demographic shift is compelling governments and healthcare systems to incorporate adult vaccination into preventive healthcare frameworks. Pharmaceutical companies are simultaneously investing in advanced vaccine formulations designed specifically for elderly populations with weakened immunity.

Countries across North America and Europe already maintain strong adult vaccination programs, while emerging economies in Asia-Pacific, Latin America, and the Middle East are steadily expanding their immunization infrastructure to improve vaccine accessibility among adults.

Governments Worldwide Intensify Adult Immunization Campaigns

Government-backed vaccination campaigns and global health initiatives are playing a transformative role in market expansion. Public health organizations such as the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) are actively promoting adult vaccination schedules and awareness campaigns to improve immunization coverage rates.

World Immunization Week 2025 further emphasized the importance of lifelong vaccination and preventive healthcare for all age groups. Governments increasingly view adult vaccination as a cost-effective approach to reducing preventable hospitalizations and minimizing the spread of infectious diseases.

Subsidized vaccination programs, occupational vaccination mandates, and public awareness campaigns are improving vaccine acceptance in both developed and developing nations. Healthcare systems are also integrating adult vaccination reminders into routine medical check-ups and digital healthcare platforms.

These efforts are especially important in regions where vaccine hesitancy and misinformation remain major obstacles to widespread immunization adoption.

Technological Innovations Accelerating Vaccine Development

Rapid advancements in vaccine technology are significantly enhancing the effectiveness, safety, and accessibility of adult vaccines. Innovations such as mRNA vaccine platforms, recombinant DNA technologies, and advanced adjuvant systems are reshaping the vaccine development landscape globally.

The success of mRNA-based COVID-19 vaccines accelerated research and investment into next-generation adult vaccines. Pharmaceutical companies are now developing multivalent and combination vaccines capable of protecting against multiple infections through a single dose.

Advanced vaccine technologies are improving shelf life, boosting immune response, and enabling faster vaccine production during disease outbreaks. This innovation pipeline is expected to create substantial growth opportunities for the adult vaccines market over the next decade.

In April 2025, Uganda introduced the R21/Matrix-M malaria vaccine into its routine immunization program, becoming the 19th African country to implement the vaccine for children in high-transmission areas.

Influenza Vaccines Continue to Dominate the Market

Among disease categories, influenza vaccines remain one of the most dominant segments within the adult vaccines industry due to recurring seasonal flu outbreaks and high infection risks among elderly and immunocompromised populations.

Annual flu vaccination recommendations by healthcare authorities worldwide continue to drive recurring demand. Pharmaceutical companies are introducing enhanced formulations such as high-dose and quadrivalent influenza vaccines to improve effectiveness against evolving flu strains.

Corporate wellness programs, hospital vaccination drives, and insurance coverage support are further strengthening influenza vaccine adoption globally.

Rising Demand for TdaP and Hepatitis Vaccines

The TdaP vaccine segment is also experiencing notable growth due to increasing awareness regarding booster immunization and maternal vaccination programs. Healthcare workers, caregivers, and pregnant women represent key target populations for TdaP vaccination initiatives.

Similarly, hepatitis vaccines remain a critical component of adult immunization programs worldwide. Vaccination efforts targeting healthcare workers, travelers, high-risk individuals, and patients with chronic liver disease continue to support steady market demand.

Global hepatitis elimination campaigns spearheaded by WHO and national governments are expected to further strengthen the market outlook over the coming years.

Meningococcal and HPV Vaccines Gain Momentum

The adult meningococcal vaccine segment is witnessing increasing adoption due to rising awareness about meningitis outbreaks and travel-related infection risks. Educational institutions, military organizations, and travel health clinics are major contributors to vaccine demand.

Meanwhile, HPV vaccines are increasingly being recommended for adults to reduce the risk of cervical cancer and other HPV-related diseases. Broader awareness regarding preventive oncology and sexually transmitted infections is positively influencing vaccine uptake rates worldwide.

United States Leads the Global Adult Vaccines Market

The United States continues to dominate the global adult vaccines market due to its robust healthcare infrastructure, strong regulatory support, and high public awareness regarding immunization. Medicare programs, private insurance coverage, and CDC recommendations ensure widespread vaccine accessibility across the country.

The country also serves as a global hub for vaccine research and innovation, with major pharmaceutical companies investing heavily in adult immunization technologies.

In October 2024, Pfizer Inc. received FDA approval for ABRYSVO, a bivalent RSV vaccine designed to prevent lower respiratory tract disease among high-risk adults aged 18 to 59 years.

Germany Strengthens Adult Immunization Programs

Germany remains one of Europe’s leading adult vaccination markets due to strong government support and universal healthcare access. The Robert Koch Institute regularly updates adult immunization recommendations, supporting high vaccine uptake rates among elderly populations.

Increasing awareness regarding shingles, pneumococcal, and influenza vaccines continues to drive market growth across the country.

In April 2025, the European Commission approved Pfizer’s Abrysvo vaccine for adults aged 18 to 59 at heightened risk of RSV-related illnesses across all 27 European Union nations.

India Emerging as a High-Potential Market

India’s adult vaccines market is growing steadily due to rising healthcare awareness, increasing chronic disease prevalence, and expanding private healthcare infrastructure. Historically dominated by pediatric immunization programs, the Indian healthcare sector is gradually shifting focus toward adult preventive care.

Urbanization, healthcare digitization, medical tourism, and pharmaceutical manufacturing capabilities are further contributing to market expansion.

In August 2024, Pfizer India partnered with Artemis Hospitals to establish a Centre for Adult Vaccination aimed at strengthening preventive healthcare awareness across India.

Saudi Arabia Expands Preventive Healthcare Investments

Saudi Arabia’s adult vaccines market is benefiting from Vision 2030 healthcare reforms, increasing healthcare expenditure, and mandatory vaccination policies for Hajj pilgrims. Influenza, meningococcal, and hepatitis vaccines remain highly demanded within the Kingdom.

The government continues investing in domestic pharmaceutical manufacturing and vaccine infrastructure to reduce dependence on imports.

In September 2023, Saudi Arabia invested approximately USD 133 million to expand local vaccine and medicine production capabilities.

Vaccine Hesitancy and High Costs Remain Key Challenges

Despite strong growth prospects, the global adult vaccines market still faces challenges related to vaccine hesitancy, misinformation, and affordability. Social media misinformation campaigns and limited healthcare literacy in several low-income regions continue to impact vaccination uptake negatively.

In many developing economies, adult vaccines remain expensive and inaccessible due to weak healthcare infrastructure, limited cold chain systems, and inadequate reimbursement programs.

Experts believe stronger public-private partnerships, awareness initiatives, and improved healthcare funding will be essential to overcoming these barriers.

Recent Developments by Leading Companies

Pfizer Inc. secured FDA approval for ABRYSVO RSV vaccine for high-risk adults aged 18–59 in October 2024.

Pfizer Inc. received European Commission approval for Abrysvo across 27 EU nations in April 2025.

Pfizer India partnered with Artemis Hospitals to establish an adult vaccination center in India during August 2024.

GlaxoSmithKline plc continued expanding its shingles and respiratory vaccine portfolio globally.

Sanofi Pasteur increased investments in advanced influenza vaccine technologies and production capacity.

AstraZeneca plc accelerated research into respiratory disease vaccines and adult immunization programs.

CSL Limited strengthened its influenza vaccine manufacturing and global distribution operations.

Uganda introduced the R21/Matrix-M malaria vaccine into routine immunization programs in April 2025.

Saudi Arabia announced a USD 133 million investment to strengthen domestic vaccine manufacturing capabilities in September 2023.

Global healthcare agencies intensified adult immunization awareness campaigns during World Immunization Week 2025.

Competitive Landscape

The global adult vaccines market remains highly competitive, with major pharmaceutical companies focusing on vaccine innovation, strategic partnerships, mergers, and production expansion. Key companies operating in the industry include:

• GlaxoSmithKline plc
• AstraZeneca plc
• Sanofi Pasteur
• Pfizer Inc.
• CSL Limited

These companies are aggressively investing in research and development to introduce next-generation vaccines with broader disease coverage, improved efficacy, and enhanced patient convenience.

Final Thoughts

The global adult vaccines market is entering a transformative growth phase driven by rising awareness about preventive healthcare, ageing demographics, technological advancements, and strong government immunization initiatives. The lessons learned from the COVID-19 pandemic have significantly accelerated global focus on adult vaccination as a long-term healthcare priority.

While challenges such as vaccine hesitancy and affordability persist, increasing investments in healthcare infrastructure, digital health systems, and vaccine innovation are expected to support sustained market growth through 2033.

As healthcare systems worldwide prioritize disease prevention and population health management, adult vaccines are poised to become one of the most critical components of modern global healthcare strategies.